{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive license to AestasRx Inc., which is located in North Carolina, to practice the inventions embodied in the following patents: U.S. Patent 8,597,660, issued December 3, 2013 (HHS reference E-144-2010/0- US-02). The patent rights in these inventions have been assigned to the United States of America. The prospective start-up exclusive license territory may be worldwide and the field of use may be limited to therapeutics (including small-molecule TFP5 mimetics) and PMA-approved diagnostics for Alzheimer's disease (intranasal delivery only), Parkinson's Disease, neuropathy, neuropathic pain, peripheral neuropathy, diabetic neuropathy, neurapraxia, axonotmesis and neurotmesis.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/04/08/2016-08097.html","cfr_references":[],"citation":"81 FR 20658","comment_url":null,"comments_close_on":"2016-04-25","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by NINDS Technology Transfer on or before April 25, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-08097","effective_on":null,"end_page":20658,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/04/08/2016-08097.xml","html_url":"https://www.federalregister.gov/documents/2016/04/08/2016-08097/prospective-grant-of-start-up-exclusive-license-therapeutics-and-pma-approved-diagnostics-for","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-08097?publication_date=2016-04-08","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-04-08/2016-08097/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":285,"last_updated":"2026-07-26 08:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-04-08/pdf/2016-08097.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-08097.pdf?1460033181","publication_date":"2016-04-08","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/04/08/2016-08097.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T21:17:46Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":20658,"subtype":null,"title":"Prospective Grant of Start-up Exclusive License: Therapeutics and PMA-Approved Diagnostics for Alzheimer's Disease (intranasal delivery), Parkinson's Disease, Neuropathy,Neuropathic Pain, Peripheral Neuropathy, Diabetic Neuropathy, Neurapraxia, Axonotmesis and Neurotmesis","toc_doc":"Therapeutics and PMA-approved Diagnostics for Alzheimer's Disease (Intranasal Delivery), etc.","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":81}